Isotretinoin for Proliferative Vitreoretinopathy

Completed · Phase 4

Conditions studied: Proliferative Vitreoretinopathy

In brief

Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.

Key facts

Study ID

NCT01445028

Run by

Wills Eye

People needed

109

Starts

2011-09-01

Expected to finish

2015-08-01

Last updated by the study team

2018-06-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-70 year-old men or 50-70 year-old, post-menopausal women.
• Healthy enough to participate in the study.
• Willing and able to consent to participation.
• Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or
• Primary RD (retinal detachment) associated with one or more high-risk features

You may not qualify if…

• History of hypersensitivity to isotretinoin.
• Current use of a corticosteroid (excluding topical).
• Any history of depression, anorexia, liver or pancreatic disease.
• More than one prior surgical RD repair.
• Patients with closed funnel retinal detachments.
• Patients with chronic retinal detachment, defined as longer than 12 weeks.
• Any use an oral retinoid within 6 months.
• Systemic chemotherapy within 6 months.
• Patients taking supplemental vitamin A.
• Corneal opacity sufficient to impair surgical view.
• Proliferative diabetic retinopathy.

Where it is running

• Wills Eye Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.